New drug combo available for BRAF-Positive melanoma patients
NCT ID NCT04489433
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides access to the drugs trametinib and dabrafenib for adults with BRAF mutation-positive metastatic melanoma that cannot be surgically removed. Participants take dabrafenib twice daily and trametinib once daily. The goal is to offer treatment to eligible patients who have no other options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dabrafenib and trametinib
- What this could lead to
- If successful, this could offer a treatment option for people with advanced melanoma who have a specific BRAF mutation.
- What could go wrong
- This is an access program, not a formal trial, so results are not systematically collected. The drugs may cause side effects like fever, rash, or heart problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF MUTATION-POSITIVE METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?